Aims: To describe genetic, clinical, anthropometric and radiological characteristics of 22 children with SHOX gene anomalies and familial short stature suggestive of Léri-Weill dyschondrosteosis. Methods: Monocentric retrospective observational study. Results: Six children (27%) presented with deletions located downstream of SHOX (mean height –1.4 ± 0.9 SDS) and 16 (68%) with either deletions encompassing SHOX, intragenic deletions or point mutations of SHOX (mean patient height for the 3 latter types of anomalies: –2.6 ± 0.8 SDS). In our sample, the two most frequently observed dysmorphic signs were clinical and/or radiological Madelung deformity (86%) and high arched palate (77%). Half the girls were born small for gestational age. Sixteen children treated with recombinant growth hormone had an increase in height from –2.7 ± 0.7 to –1.4 ± 0.7 SDS. Four children achieved adult height (–2.0 ± 0.9 SDS) with a gain over baseline height of 1.0 ± 0.5 SDS after a mean treatment duration of 5.8 ± 2.1 years. Conclusion: Patients shared common clinical, anthropometric and radiological signs but their height deficit varied, depending on the type of the SHOX gene anomaly. Due to the small size of our sample, our findings need to be confirmed in a larger population of patients.

Keywords:
Léri-Weill dyschondrosteosis, SHOX gene, Growth hormone treatment, Final heights
1.
Léri A, Weill J: Une affection congénitale et symétrique du développement osseux. La dyschondrostéose. Bull Mém Soc Med Hôp Paris 1929;35:1491–1494.
2.
Huber C, Rosilio M, Munnich A, Cormier-Daire V, French SHOX GeNeSIS Module: High incidence of SHOX anomalies in individuals with short stature. J Med Genet 2006;43:735–739.
3.
Binder G, Renz A, Martinez A, Keselman A, Hesse V, Riedl SW, Häusler G, Fricke-Otto S, Frisch H, Heinrich JJ, Ranke MB. SHOX haploinsufficiency and Léri-Weill dyschondrosteosis: prevalence and growth failure in relation to mutation, sex, and degree of wrist deformity. J Clin Endocrinol Metab 2004;89:4403–4408.
4.
Ross JL, Scott C Jr, Marttila P, Kowal K, Nass A, Papenhausen P, Abboudi J, Osterman L, Kushner H, Carter P, Ezaki M, Elder F, Wei F, Chen H, Zinn AR: Phenotypes associated with SHOX deficiency. J Clin Endocrinol Metab 2001;86:5674–5680.
5.
Grigelioniene G, Schoumans J, Neumeyer L, Ivarsson S, Eklöf O, Enkvist O, Tordai P, Fosdal I, Myhre AG, Westphal O, Nilsson NO, Elfving M, Ellis I, Anderlid BM, Fransson I, Tapia-Paez I, Nordenskjöld M, Hagenäs L, Dumanski JP: Analysis of short stature homeobox-containing gene (SHOX) and auxological phenotype in dyschondrosteosis and isolated Madelung deformity. Human Genet 2001;109:551–558.
6.
Schiller S, Spranger S, Schechinger B, Fukami M, Merker S, Drop SL, Tröger J, Knoblauch H, Kunze J, Seidel J, Rappold GA: Phenotypic variation and genetic heterogeneity in Léri-Weill syndrome. Eur J Hum Genet 2000;8:54–62.
7.
Shears DJ, Vassal HJ, Goodman FR, Palmer RW, Reardon W, Superti-Furga A, Scambler PJ, Winter R: Mutation and deletion of the pseudoautosomal gene SHOX cause Léri-Weill dyschondrosteosis. Nat Genet 1998;19:70–73.
8.
Marchini A, Rappold G, Schneider KU: SHOX at a glance: from gene to protein. Arch Physiol Biochem 2007;113:116–123.
9.
Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA: Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997;16:54–63.
10.
Blaschke RJ, Rappold GA: SHOX, growth, Léri-Weill and Turner syndromes. Trends Endocrinol Metab 2000;11:227–230.
11.
Belin V, Cusin V, Viot G, Girlich D, Toutain A, Moncla A, Vekemans M, Le Merrer M, Munnich A, Cormier-Daire V: SHOX mutations in dyschondrosteosis (Léri-Weill syndrome). Nat Genet 1998;19:67–69.
12.
Huber C, Cusin V, Le Merrer M, Mathieu M, Sulmont V, Dagoneau N, Munnich A, Cormier-Daire V: SHOX point mutations in dyschondrosteosis. J Med Genet 2001;38:323.
13.
Benito-Sanz S, Thomas NS, Huber C, Gorbenko del Blanco D, Aza-Carmona M, Crolla JA, Maloney V, Rappold G, Argente J, Campos-Barros A, Cormier-Daire V, Heath KE: A novel class of pseudoautosomal region 1 deletions downstream of SHOX is associated with Léri-Weill dyschondrosteosis. Am J Hum Genet 2005;77:533–544.
14.
Usher R, McLean F: Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 1969;74:901–910.
15.
Sempe M, Pedron G, Roy-Pernot MP: Auxologie, méthodes et sequences. Paris, Théraplix, 1979.
16.
Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C, Charraud A: Body Mass Index variations: centiles from birth to 87 years. Eur J Clin Nutr 1991;45:13–21.
17.
Frederiks AM, van Buuren S, van Heel WJM, Dijkman-Neerincx RHM, Verloove-Vanhorick SP, Wit JM: Nationwide age references for sitting height, leg length, and sitting height/height ratio, and their diagnostic value for disproportionate growth disorders. Arch Dis Child 2005;90:807–812.
18.
Flügel B, Greil H, Sommer K: Anthropologischer Atlas: Alters und Geschlechtsvariabilität des Menschen: Grundlagen und Daten. Frankfurt am Main, Wötzel, 1986.
19.
Kosowicz J: The carpal sign in gonadal dysgenesis. J Clin Endocrinol Metab 1962;22:949–952.
20.
Bayley N, Pinneau SR: Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423–441.
21.
Greulich W, Pyle S: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
22.
Rappold G, Blum WF, Shavrikova EP, Crowe BJ, Roeth R, Quigley CA, Ross JL, Niesler B: Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J Med Genet 2007;44:306–313.
23.
Ross JL, Kowal K, Quigley CA, Blum WF, Cutler GB Jr, Crowe B, Hovanes K, Elder FF, Zinn AR: The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: contrasting children with Léri-Weill dyschondrosteosis and Turner syndrome. J Pediatr 2005;147:499–507.
24.
Tauber M, Lounis N, Coullet J, Rochiccioli P: Études des signes osseux évoquant une anomalie du gene SHOX dans le syndrome de Turner. Act Endocrinol Pediatr 2001:99–109.
25.
Binder G, Fritsch H, Schweizer R, Ranke MB: Radiological signs of Léri-Weill dyschondrosteosis in Turner Syndrome. Horm Res 2001;55:71–76.
26.
Blum WF, Cao D, Hesse V, Fricke-Otto S, Ross JL, Jones C, Quigley CA, Binder G: Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome. Horm Res 2009:71:167–172.
27.
Blum WF, Crowe BJ, Quigley CA, Jung H, Cao D, Ross JL, Braun L, Rappold G, SHOX Study Group: Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:219–228.
28.
Thuestad IJ, Iversson SA, Nilsson KO, Wattsgård C: Growth hormone treatment in Léri-Weill syndrome. J Pediatr Endocrinol Metab 1996;9:201–204.
29.
Binder G, Schwarze CP, Ranke MB: Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone. J Clin Endocrinol Metab 2000;85:245–249.
30.
Ogata T, Onigata K, Hotsubo T, Matsuo N, Rappold G. Growth hormone and gonadotropin-releasing hormone analog therapy in haploinsufficiency of SHOX. Endocr J 2001;48:317–322.
31.
Munns CF, Berry M, Vickers D, Rappold GA, Hyland VJ, Glas IA, Batch JA. Effect of 24 months of recombinant growth hormone on height and body proportions in SHOX haploinsufficiency. J Pediatr Endocrinol Metab 2003;16:997–1004.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.